Menu Search
Equities

Fortrea Holdings Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
K67:STU

Fortrea Holdings Inc

Actions
  • Price (EUR)11.10
  • Today's Change-0.300 / -2.63%
  • Shares traded0.00
  • 1 Year change-21.28%
  • Beta--
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

  • Revenue in USD (TTM)2.76bn
  • Net income in USD-1.03bn
  • Incorporated2023
  • Employees14.50k
  • Location
    Fortrea Holdings Inc8 Moore DriveDURHAM 27709United StatesUSA
  • Fax+1 (302) 636-5454
  • Websitehttps://www.fortrea.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.